S Popat1, A Curioni-Fontecedro2, U Dafni3, R Shah4, M O'Brien5, A Pope6, P Fisher7, J Spicer8, A Roy9, D Gilligan10, O Gautschi11, E Nadal12, W D Janthur13, R López Castro14, R García Campelo15, S Rusakiewicz16, I Letovanec17, V Polydoropoulou18, H Roschitzki-Voser19, B Ruepp19, A Gasca-Ruchti19, S Peters20, R A Stahel21. 1. Royal Marsden Hospital Fulham Road, London, UK. 2. University Hospital Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland. 3. National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece. 4. Kent Oncology Centre, Maidstone, UK. 5. Royal Marsden Hospital Sutton, London, UK. 6. Clatterbridge Cancer Centre, Liverpool, UK. 7. Weston Park Hospital, Sheffield, UK. 8. King's College London, Guy's Hospital, London, UK. 9. University Hospital Plymouth, Plymouth, UK. 10. Addenbrooke's Hospital, Cambridge, UK. 11. University of Bern and Cantonal Hospital Luzern, Luzern Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Swiss Group for Clinical Cancer Research, Switzerland (SAKK), Bern. 12. Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain. 13. Swiss Group for Clinical Cancer Research, Switzerland (SAKK), Bern; Cantonal Hospital Aarau, Aarau, Switzerland. 14. Hospital Clínico Universitario de Valladolid, Valladolid, Spain. 15. Hospital Teresa Herrera, La Coruña, Spain. 16. Centre Hospitalier Universitaire Vaudois CHUV, Centre of Experimental Therapies and Department of Oncology, Lausanne, Switzerland. 17. Centre Hospitalier Universitaire Vaudois CHUV, Institute of Pathology, Lausanne, Switzerland. 18. Frontier Science Foundation-Hellas, Athens, Greece. 19. European Thoracic Oncology Platform (ETOP), Bern, Switzerland. 20. Centre Hospitalier Universitaire Vaudois, Department of Oncology, Lausanne, Switzerland. 21. University Hospital Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland. Electronic address: Rolf.Stahel@etop-eu.org.
Abstract
BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. PATIENTS AND METHODS: PROMISE-meso is an open-label 1:1 randomised phase III trial investigating the efficacy of pembrolizumab (200 mg/Q3W) versus institutional choice single-agent chemotherapy (gemcitabine or vinorelbine) in relapsed MPM patients with progression after/on previous platinum-based chemotherapy. Patients were performance status 0-1 and unselected for programmed cell death ligand 1 (PD-L1) status. At progression, patients randomly assigned to receive chemotherapy were allowed to crossover to pembrolizumab. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR). Secondary end points were overall survival (OS), investigator-assessed PFS, objective response rate (ORR), and safety. Efficacy by PD-L1 status was investigated in exploratory analyses. RESULTS:Between September 2017 and August 2018, 144 patients wererandomly allocated (pembrolizumab: 73; chemotherapy: 71). At data cut-off [20 February 2019, median follow-up of 11.8 months (interquartile range: 9.9-14.5)], 118 BICR-PFS events were observed. No difference in BICR-PFS was detected [hazard ratio = 1.06, 95% confidence interval (CI): 0.73-1.53; P = 0.76], and median BICR-PFS (95% CI) for pembrolizumab was 2.5 (2.1-4.2), compared with 3.4 (2.2-4.3) months for chemotherapy. A difference in ORR for pembrolizumab was identified (22%, 95% CI: 13% to 33%), over chemotherapy (6%, 95% CI: 2% to 14%; P = 0.004). Forty-five patients (63%) assigned to chemotherapy received pembrolizumab at progression. With follow-up to 21 August 2019 [17.5 months: (14.8-19.7)], no difference in OS was detected between groups (HR = 1.12, 95% CI: 0.74-1.69; P = 0.59), even after adjusting for crossover. Pembrolizumab safety was consistent with previous observations. Exploratory efficacy analyses by PD-L1 status demonstrated no improvements in ORR/PFS/OS. CONCLUSION: This is the first randomised trial evaluating the efficacy of pembrolizumab in MPM patients progressing after/on previous platinum-based chemotherapy. In biologically unselected patients, although associated with an improved ORR, pembrolizumab improves neither PFS nor OS over single-agent chemotherapy.
RCT Entities:
BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. PATIENTS AND METHODS: PROMISE-meso is an open-label 1:1 randomised phase III trial investigating the efficacy of pembrolizumab (200 mg/Q3W) versus institutional choice single-agent chemotherapy (gemcitabine or vinorelbine) in relapsed MPM patients with progression after/on previous platinum-based chemotherapy. Patients were performance status 0-1 and unselected for programmed cell death ligand 1 (PD-L1) status. At progression, patients randomly assigned to receive chemotherapy were allowed to crossover to pembrolizumab. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR). Secondary end points were overall survival (OS), investigator-assessed PFS, objective response rate (ORR), and safety. Efficacy by PD-L1 status was investigated in exploratory analyses. RESULTS: Between September 2017 and August 2018, 144 patients were randomly allocated (pembrolizumab: 73; chemotherapy: 71). At data cut-off [20 February 2019, median follow-up of 11.8 months (interquartile range: 9.9-14.5)], 118 BICR-PFS events were observed. No difference in BICR-PFS was detected [hazard ratio = 1.06, 95% confidence interval (CI): 0.73-1.53; P = 0.76], and median BICR-PFS (95% CI) for pembrolizumab was 2.5 (2.1-4.2), compared with 3.4 (2.2-4.3) months for chemotherapy. A difference in ORR for pembrolizumab was identified (22%, 95% CI: 13% to 33%), over chemotherapy (6%, 95% CI: 2% to 14%; P = 0.004). Forty-five patients (63%) assigned to chemotherapy received pembrolizumab at progression. With follow-up to 21 August 2019 [17.5 months: (14.8-19.7)], no difference in OS was detected between groups (HR = 1.12, 95% CI: 0.74-1.69; P = 0.59), even after adjusting for crossover. Pembrolizumab safety was consistent with previous observations. Exploratory efficacy analyses by PD-L1 status demonstrated no improvements in ORR/PFS/OS. CONCLUSION: This is the first randomised trial evaluating the efficacy of pembrolizumab in MPM patients progressing after/on previous platinum-based chemotherapy. In biologically unselected patients, although associated with an improved ORR, pembrolizumab improves neither PFS nor OS over single-agent chemotherapy.
Authors: Farhad Kosari; Maria Disselhorst; Jun Yin; Tobias Peikert; Julia Udell; Sarah Johnson; James Smadbeck; Stephen Murphy; Alexa McCune; Giannoula Karagouga; Aakash Desai; Janet Schaefer-Klein; Mitesh J Borad; John Cheville; George Vasmatzis; Paul Baas; Aaron S Mansfield Journal: J Thorac Oncol Date: 2021-11-17 Impact factor: 15.609
Authors: L Gutierrez-Sainz; P Cruz; S Martinez-Recio; O Higuera; M I Esteban-Rodriguez; F Arias-Lotto; R A Gonzalez; J De Castro-Carpeño Journal: Clin Transl Oncol Date: 2021-04-10 Impact factor: 3.405
Authors: Gauri R Varadhachary; Daniel M Halperin; Kanwal Raghav; Suyu Liu; Michael J Overman; Anneleis F Willett; Mark Knafl; Szu-Chin Fu; Anais Malpica; Seema Prasad; Richard E Royal; Christopher P Scally; Paul F Mansfield; Ignacio I Wistuba; Andrew P Futreal; Dipen M Maru; Luisa M Solis Soto; Edwin R Parra Cuentas; Honglei Chen; Pamela Villalobos; Anuj Verma; Armeen Mahvash; Patrick Hwu; Patricia Cortazar; Edward McKenna; Cindy Yun; Shannon Dervin; Katja Schulze; Walter C Darbonne; Ajaykumar C Morani; Scott Kopetz; Keith F Fournier; Scott E Woodman; James C Yao Journal: Cancer Discov Date: 2021-07-14 Impact factor: 39.397